Tenofovir alafenamide
- Generic Name
- Tenofovir alafenamide
- Brand Names
- Biktarvy, Descovy, Genvoya, Odefsey, Vemlidy
- Drug Type
- Small Molecule
- Chemical Formula
- C21H29N6O5P
- CAS Number
- 379270-37-8
- Unique Ingredient Identifier
- EL9943AG5J
- Background
Tenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal diffusion. Tenofov...
- Indication
Tenofovir alafenamide is indicated for the treatment of hepatitis B virus infection in adults and pediatric patients 12 years of age and older with compensated liver disease.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Pre-Exposure Prophylaxis (PrEP)
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 412
- Registration Number
- NCT05979311
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 120
- Registration Number
- NCT05652478
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
- Conditions
- Interventions
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05467553
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 272
- Registration Number
- NCT05453448
- Locations
- 🇨🇳
Wenting Peng, Changsha, China
Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 1800
- Registration Number
- NCT05423834
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT05275023
- Locations
- 🇪🇸
Hosp. Univ. Pta. de Hierro Majadahonda, Madrid, Spain
🇬🇧Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom
🇫🇷Hopital Beaujon, Clichy, France
The Efficacy of Prophylactic TAF for HBsAg-positive Patients Receiving bDMARDs
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 108
- Registration Number
- NCT05001672
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Jidong Jia
- Target Recruit Count
- 100
- Registration Number
- NCT04939441
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
🇨🇳Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Shuguang Hospital, Shanghai, Shanghai, China
PK of TAF and TDF for PrEP in Pregnant and Postpartum Women
- Conditions
- Interventions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 50
- Registration Number
- NCT04937881
- Locations
- 🇿🇦
Gugulethu Midwife Obstetric Unit, Cape Town, South Africa
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 103
- Registration Number
- NCT04891770
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇩🇰Odense University Hospital, Odense, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.